Optimizing Outcomes For Patients With Lung Cancer: Checkpoint Inhibitor Therapy in SCLC and Improving Health Literacy

VINDICO
8/26/20, 11:00 PM
America/New York GMT -4 summer

Description

Lung cancer continues to be the major cause of cancer-related death worldwide. Advances in diagnosis and treatment of lung cancer are helping to improve the management of these patients, yet health disparities persist. Many of these disparities are difficult to overcome, yet strategies to address others such as health literacy are currently being evaluated. Small-cell lung cancer (SCLC), which accounts for approximately 13% of all lung cancer cases, is the most aggressive type of lung cancer and is associated with rapid recurrence and poor prognosis. Immune checkpoint inhibitors alone or in combination with chemotherapy have been demonstrated to be an effective therapeutic option providing overall survival benefits to SCLC patients. In this educational symposium, experts in the field will evaluate checkpoint inhibitors in the management of SCLC, discuss health disparities in lung cancer, and provide guidance to address health literacy in patients with lung cancer.

Previous registration necessary?

NO

YES
Simultaneous translation ?

NO

YES
Will it be recorded?
NO
YES

Optimizing Outcomes For Patients With Lung Cancer: Checkpoint Inhibitor Therapy in SCLC and Improving Health Literacy

Inglês

 

Speakers

George R. Simon, Yasir Y. Elamin, Sarah Anderson, Kelly Brassil

 

Link to the Event

Banner to the Event

Optimizing Outcomes For Patients With Lung Cancer: Checkpoint Inhibitor Therapy in SCLC and Improving Health Literacy